| References |
|
|
Abbruzzese JL
(2002)
New applications of gemcitabine and future directions in the management of pancreatic cancer.
Cancer
95:
941–945.
|
|
|
Bardeesy N and
DePinho R
(2002)
Pancreatic cancer biology and genetics.
Nature Reviews Cancer
2:
897–909.
|
|
|
Bashyam MD,
Bair R,
Kim YH et al.
(2005)
Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer.
Neoplasia
7(6):
556–562.
|
|
|
Biankin AV,
Kench JG,
Morey AL et al.
(2001)
Overexpression of p21WAF/CIP1 is an early event in the development of pancreatic intraepithelial neoplasia.
Cancer Research
61:
8830–8837.
|
|
|
Brune K,
Hong S-M,
Li A et al.
(2008)
Genetic and epigenetic alterations of familial pancreatic cancers.
Cancer Epidemiology Biomarkers and Prevention
17:
3536–3542.
|
|
|
Calhoun ES,
Jones JB,
Ashfaq R et al.
(2003)
BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets.
American Journal of Pathology
163(4):
1255–1260.
|
|
|
Ebert M,
Schandl L and
Schmid R
(2001)
Differentiation of chronic pancreatitis from pancreatic cancer: recent advances in molecular diagnosis.
Digestive Diseases and Sciences
19:
32–36.
|
|
|
Gao J,
Song J,
Huang H et al.
(2010)
Methylation of the SPARC gene promoter and its clinical implications in pancreatic cancer.
Journal of Experimental and Clinical Cancer Research
29:
28.
|
|
|
Greer J and
Whitcomb D
(2007)
Role of BRCA 1 and BRCA 2 mutations in pancreatic cancer.
Gut
56:
601–605.
|
|
|
Hahn SA,
Schutte M,
Hoque AT et al.
(1996)
DPC4, a candidate tumor-suppressor gene at human chromosome 18q21.1.
Science
271:
350–353.
|
|
|
Harada T,
Chelala C,
Bhakta V et al.
(2008)
Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays.
Oncogene
27:
1951–1960.
|
|
|
Harada T,
Chelala C,
Crnogorac-Jurcevic T and
Lemoine NR
(2009)
Genome-wide analysis of pancreatic cancer using microarray-based techniques.
Pancreatology
9:
13–24.
|
|
|
van der Heijden MS,
Brody JR,
Gallmeier E et al.
(2004)
Functional defects in the Fanconi anemia pathway in pancreatic cancer cells.
American Journal of Pathology
165(2):
651–657.
|
|
|
Hruban RH,
van Mansfeld ADM,
Offerhaus GJ et al.
(1993)
K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.
American Journal of Pathology
143(2):
545–554.
|
|
|
Hruban RH,
Wilentz RE and
Kern SE
(2000)
Genetic progression in the pancreatic ducts.
American Journal of Pathology
156:
1821–1825.
|
|
|
Hustinx SR,
Leoni LM,
Yeo CJ et al.
(2005)
Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion.
Modern Pathology
18(7):
959–963.
|
|
|
Jemal A,
Siegel R,
Ward E et al.
(2009)
Cancer statistics, 2009.
CA: A Cancer Journal for Clinicians
59:
225–249.
|
|
|
Jones S,
Hruban RH,
Kamiyama M et al.
(2009)
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene.
Science
324(5924):
217.
|
|
|
Kinzler KW and
Vogelstein B
(1997)
Cancer-susceptibility genes: gate-keepers and caretakers.
Nature
386:
761–763.
|
|
|
Kitada T,
Seki S,
Sakaguchi H et al.
(2003)
Clinicopathological significance of hypoxia-inducible factor-1a expression in human pancreatic carcinoma.
Histopathology
43:
550–555.
|
|
|
Kubo T,
Kuroda Y,
Kokubu A et al.
(2009)
Resequencing analysis of the human tyrosine kinase gene family in pancreatic cancer.
Pancreas
38:
e200–e206.
|
|
|
Kuwahara K,
Sasaki T,
Kuwada Y et al.
(2003)
Expression of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival.
Pancreas
26:
344–349.
|
|
|
Li D,
Suzuki H,
Liu B et al.
(2009)
DNA repair gene polymorphisms and risk of pancreatic cancer.
Clinical Cancer Research
15(2):
740–746.
|
|
|
Longo R,
Cacciamani F,
Naso G and
Gasparini G
(2008)
Pancreatic cancer: from molecular signature to target therapy.
Critical Reviews in Oncology/Hematology
68:
197–211.
|
|
|
Low S-K,
Kuchiba A,
Zembutsu H et al.
(2010)
Genome-wide association study of pancreatic cancer in Japanese population.
PLoS ONE
5:
e11824.
|
|
|
Luttges J,
Galehdari H,
Brocker V et al.
(2001)
Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis.
American Journal of Pathology
158:
1677–1683.
|
|
|
Maitra A,
Adsay NV,
Argani P et al.
(2003)
Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray.
Modern Pathology
16:
902–912.
|
|
|
Maitra A,
Kern SE and
Hruban RH
(2006)
Molecular pathogenesis of pancreatic cancer.
Best Practice and Research Clinical Gastroenterology
20:
211–226.
|
|
|
Malumbres M and
Pellicer A
(1998)
RAS pathways to cell cycle control and cell transformation.
Frontiers in Bioscience
3:
d887–d912.
|
|
|
Neoptolemos JP,
Dunn JA,
Stocken DD et al.
(2001)
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer. A randomized controlled trial.
Lancet
358:
1576–1585.
|
|
|
Oft M,
Peli J,
Rudaz C et al.
(1996)
TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells.
Genes & Development
10:
2462–2477.
|
|
|
Oliveira-Cunha M,
Siriwardena AK and
Byers R
(2008)
Molecular diagnosis in pancreatic cancer.
Diagnostic Histopathology
14:
214–222.
|
|
|
Parker JF,
Florell SR,
Alexander A et al.
(2003)
Pancreatic carcinoma surveillance in patients with familial melanoma.
Archives of Dermatology
139(8):
1019–1025.
|
|
|
Pogue-Geile KL,
Chen R,
Bronner MP et al.
(2006)
Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism.
PLoS Medicine
3:
e516.
|
|
|
Redston MS,
Caldas C,
Seymour AB et al.
(1994)
p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions.
Cancer Research
54(11):
3025–3033.
|
|
|
Rozenblum E,
Schutte M,
Goggins M et al.
(1997)
Tumor-suppressive pathways in pancreatic carcinoma.
Cancer Research
57:
1731–1734.
|
|
|
Schutte M,
Hruban RH,
Geradts J et al.
(1997)
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.
Cancer Research
57:
3126–3130.
|
|
|
Schwarte-Waldhoff I,
Volpert OV,
Bouck NP et al.
(2000)
Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis.
Proceedings of the National Academy of Sciences of the USA
97:
9624–9629.
|
|
|
Su GH,
Bansal R,
Murphy KM et al.
(2001)
ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma.
Proceedings of the National Academy of Sciences of the USA
98(6):
3254–3257.
|
|
|
Subramanian G,
Schwarz RE,
Higgins L et al.
(2004)
Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Cancer Research
64:
5200–5211.
|
|
|
Talar-Wojnarowska T and
Malecka-Panas E
(2006)
Molecular pathogenesis of pancreatic adenocarcinoma potential clinical implications.
Medical Science Monitor
12:
186–193.
|
|
|
Thayer SP,
di Magliano MP,
Heiser PW et al.
(2003)
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis.
Nature
425:
851–856.
|
|
|
Tjarda van Heek N,
Meeker AK,
Kern SE et al.
(2002)
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia.
American Journal of Pathology
161:
1541–1547.
|
|
|
Uehara H,
Miyamoto M,
Kato K et al.
(2004)
Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma.
Cancer Research
64:
3533–3537.
|
|
|
Vitone LJ,
Greenhalf W,
McFaul CD and
Neoptolemos JP
(2006)
The inherited genetics of pancreatic cancer and prospects for secondary screening.
Best Practice and Research Clinical Gastroenterology
20:
253–283.
|
|
|
Welsh J,
Sapinoso L,
Kern S et al.
(2003)
Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum.
Proceedings of the National Academy of Sciences of the USA
100:
3410–3415.
|
|
|
Wong HH and
Lemoine NR
(2008)
Biologic approaches to therapy of pancreatic cancer.
Pancreatology
8:
431–461.
|
|
|
Xiong HQ and
Abbruzzese JL
(2002)
Epidermal growth factor receptor targeted therapy for pancreatic cancer.
Seminars in Oncology
29(suppl. 14):
31–37.
|
|
|
Yamamoto H,
Itoh F,
Nakamura H et al.
(2001)
Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability.
Cancer Research
61(7):
3139–3144.
|
| Further Reading |
|
|
Belda-Iniesta C,
Ibanez de Caceres I,
Barriuso J et al.
(2008)
Molecular biology of pancreatic cancer.
Clinical and Translational Oncology
10:
530–537.
|
|
|
Feldmann G,
Beaty R,
Hruban RH and
Maitra A
(2007)
Molecular genetics of pancreatic intraepithelial neoplasia.
Journal of Hepato-Biliary-Pancreatic Surgery
14:
224–232.
|
|
|
Feldmann G and
Maitra A
(2009)
Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts.
Journal of Molecular Diagnostics
10:
111–122.
|
|
|
Furukawa T
(2009)
Molecular pathology of pancreatic cancer: implications for molecular targeting therapy.
Clinical Gastroenterology and Hepatology
7:
S35–S39.
|
|
|
Grote T and
Lonsdon CD
(2007)
Progress on molecular markers of pancreatic cancer.
Current Opinion in Gastroenterology
23:
508–514.
|
|
|
Mihaljevic AL,
Michalski CW,
Friess H and
Kleeff J
(2010)
Molecular mechanisms of pancreatic cancer.
Langenbeck's Archives of Surgery
395:
295–308.
|
|
|
Rachagani S,
Kumar S and
Batra SK
(2010)
MicroRNA in pancreatic cancer: pathological, diagnostic, and therapeutic implications.
Cancer Letters
292:
8–16.
|
|
|
Schneider G,
Hamacher R,
Eser S et al.
(2008)
Molecular biology of pancreatic cancer – new aspects and targets.
Anticancer Research
28(3A):
1541–1550.
|
